HIV & AIDS
Tuberculosis
Malaria
The Global Fund / John Rae
-
News
Global Fund Grant in the Democratic People’s Republic of Korea
The Global Fund has reached agreement with partners for a consolidated grant for tuberculosis and malaria in the Democratic People’s Republic of Korea, and implementation of the grant has begun.
Read more -
News
Agence Française de Développement and the Global Fund Strengthen Partnership to Build Resilient Systems for Health
On the occasion of President Emmanuel Macron's visit to Côte d'Ivoire, Rémy Rioux, Chief Executive Officer of Agence Française de Développement, and Peter Sands, Executive Director of the Global Fund, signed a partnership agreement to end epidemics and build sustainable systems for health in West and Central Africa, two regions where these challenges are particularly acute.
Read more -
News
Highest-Ever Funding Allocations Announced to Fight AIDS, TB and Malaria
Following a record-breaking Replenishment in October 2019, the Global Fund today announced its largest-ever funding allocations for eligible countries to fight AIDS, tuberculosis and malaria and build systems for health over the next three years.
Read more -
News
Global Fund Praises PEPFAR’s Leadership and Results
The Global Fund to Fight AIDS, Tuberculosis and Malaria applauded strong leadership by the U.S. President's Emergency Plan for AIDS Relief, known as PEPFAR, which announced its latest results showing 18 million lives saved through accountable, transparent and cost-effective investments.
Read more -
News
Global Fund Board Steps Up Efforts to Expand Impact Against HIV, TB and Malaria
The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria approved funding decisions for ambitious investments over the next three-year period to significantly increase impact against HIV, TB and malaria and to build resilient and sustainable systems for health.
Read more -
News
Landmark Deal Secures Significant Discount on Price of Medicine to Prevent TB
A landmark agreement announced today by Unitaid, the Global Fund to Fight AIDS, Tuberculosis and Malaria and global biopharmaceutical company Sanofi will significantly lower the price of rifapentine, a critically important drug used to prevent tuberculosis.
Read more